FINALLY OVER: A decadelong patent infringement battle over blood thinner Plavix ends with generic drugmaker Apotex Corp. paying about $445 million to Bristol-Myers Squibb and Sanofi. They jointly sell the world's second-best-selling drug.
GENERICS COMING: Plavix gets U.S. generic competition in May. In 2006, Bristol and Sanofi agreed to pay Apotex $40 million to delay selling generic Plavix until 2011 and to end its challenge of the Plavix patent.
BACKLASH: The deal with Apotex was illegal, leading to a federal criminal antitrust probe and the ouster of a former Bristol CEO.